Inactive Instrument
Anacor Pharmaceuticals Inc Share Price
Stocks
US0324201013
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 26/05/16 | Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing | RE |
| 16/05/16 | Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel | RE |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 79 | 31/01/2004 | |
Margaret Madden
PRN | Corporate Officer/Principal | - | 23/06/2016 |
| General Counsel | 77 | 31/12/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Margaret Madden
BRD | Director/Board Member | - | 23/06/2016 |
Bryan Supran
BRD | Director/Board Member | - | 23/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +21.92% | +74.60% | 57.39B | |
| +0.89% | -0.63% | +4.28% | +34.51% | 47.64B | |
| +0.36% | +0.81% | +352.17% | +689.61% | 44.29B | |
| -0.96% | -4.50% | +26.36% | +33.18% | 42.5B | |
| -0.20% | -0.77% | +3.74% | +100.60% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | |
| -2.68% | +2.92% | +29.63% | +19.50% | 28.53B | |
| +0.05% | -1.64% | -7.28% | -14.06% | 24.34B | |
| Average | -0.23% | -0.59% | +54.39% | +120.28% | 43.39B | |
| Weighted average by Cap. | +0.12% | -0.84% | +58.77% | +129.91% |
- Stock Market
- Stocks
- Stock
Select your edition
All financial news and data tailored to specific country editions
